The #TexasLung23 conference named one of the 10 'Conferences that Captivate' in 2023! Proud to co-chair TLC Conference with Dr. Tina Cascone. Thanks to all who made it a success & hope to see everyone April 18-20 for @TexasLung24 at Austin City Limits!

bizbash.com/bizbash-lists/…

In this episode, host Stephen V Liu, MD leads a discussion on the role of neoadjuvant therapy for stage III #NSCLC using a virtual tumor board format. Guests include Linda Martin from the University of Virginia, & @JairBar from the Tel Aviv University: bit.ly/VTBN #LCSM

Honored to chair this year's Medscape Perspectives in Lung Cancer Care where we'll discuss current practices and controversies in NSCLC. Virtual meeting, April 11-12, 2024. Mark your calendar, more details to come!

Data on incidentally detected lung cancer in pts too old or too young for LDCT criteria JTO & JTO CRR from Dr. Raymond Osarogiagbon, MBBS, FACP et al. Lower rights of early stage, higher rates of later stage. Value of lung nodule program demonstrated here.

jto.org/article/S1556-…

Watch now - EGFR Resisters 5th Annual Research Summit Wrap Up w/ commentary from Stephen V Liu, MD & Ivy Elkins.
Congratulations to the young investigators! Thank you CE Concepts for sponsoring this event!

EGFR Resisters Research Summit #lcam #lcsm

youtube.com/watch?v=tniPDA…

Supported by data from the Phase 3 MARIPOSA-2 study, #MyCompany submitted a sBLA to the U.S. FDA for the treatment of patients with locally advanced or metastatic EGFRm NSCLC after treatment with osimertinib.

bit.ly/47mpsq3

#MyCompany #Innovation #PrecisionMedicine

Patient reported outcomes from POSEIDON now Lung Cancer Journal. First line tremelimumab,  durvalumab, and chemotherapy for NSCLC delayed deterioration in QoL vs chemotherapy alone and adding tremelimumab (CTLA4) did not significantly worsen PROs.

lungcancerjournal.info/article/S0169-…

Thank you to all my friends and brothers and sisters in thoracic oncology for coming to the 1st annual MaTOS Conference. Stephen Liu had the idea to take this beautiful picture showing in the back the landscape of Albuquerque. Stephen V Liu, MD IASLC The Medical Educator Consortium The Oncology Institute

The #TexasLung23 conference named one of the 10 'Conferences that Captivate' in 2023! Proud to co-chair TLC Conference with Dr. Tina Cascone. Thanks to all who made it a success & hope to see everyone April 18-20 for @TexasLung24 at Austin City Limits!

bizbash.com/bizbash-lists/…

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the Board of Directors International Seat.

Visit asco.org/election to learn more about the candidates and place your votes!

ASCO OncLive.com Journal of Clinical Oncology ASCOPost Grupo Oncoclínicas

Very limited data on safety of targeted therapy during pregnancy. One case report Clinical Lung Cancer of alectinib for #ALK NSCLC started at week 18 of gestation with an uncomplicated delivery at 39 weeks.

clinical-lung-cancer.com/article/S1525-…

Dr. Jonathan Riess, MD MS closes out #MaTOS23 with an overview of thymic malignancies. Immunotherapy active but toxic in thymic carcinoma (too toxic for thymoma). Great results with carboplatin + paclitaxel + ramucirumab in the RELEVENT trial by Dr. Claudia Proto

Outstanding discussion of systemic therapy for mesothelioma by Dr. Jorge Gomez at #MaTOS23 . Immunotherapy is active but room for improvement. Loved the point on the need for collaboration. Lots of small studies focused on potential targets. Need larger trials to guide us.

How can we utilize radiation to promote immune responses in NSCLC? Dr. Jeff Bradley, MD at #MaTOS23 outlines the rationale and highlights studies lighting the way, like this ongoing phase II from Dr. Brendon Stiles.

Dr. raja flores offers perspective on MARS2 and surgery for mesothelioma at #MaTOS23 . Concerns include the operation (“extended” pleurectomy), no PET, inclusion of sarcomatoid, and 9% 90d mortality. Do these explain the lack of survival benefit with surgery in MARS2?

Wealth of options to deliver immunotherapy in NSCLC. Survey of the field, how we approach treatment, and what the immediate future holds from this expert panel at #MaTOS23 with Drs. Jyoti D Patel Dr. Luis E. Raez Ferdinandos Skoulidis Millie Das MD Ticiana Batista (Leal)

Masters of Thoracic Oncology #MATOS23 Summit!
Faculty Karen Reckamp, MD, MS Edgardo.S.Santos.MD.FACP Stephen V Liu, MD Hossein Borghaei, DO raja flores Fred R. Hirsch Julia Rotow MD JessicaJLinMD Karen Kelly Stephen V Liu, MD LudaBazhenovaMD Corey Langer IASLC The Medical Educator Consortium Dr. Estela Rodriguez Jyoti D Patel…

Fun and engaging tumor boards at #MaTOS23 with Drs. Corey Langer Mary Jo Fidler Edgardo S. Santos, M.D., FACP Sally Lau Millie Das MD Jonathan Riess, MD MS Julia Rotow MD

So great discussing the state of lung cancer with these amazing #MaTOS23 faculty!